Latest Regulatory Reforms News

Ryman Healthcare has unveiled a refreshed strategy focused on growing recurring earnings and optimising its portfolio, targeting a $150 million sustainable cash flow improvement and $500 million cash release by FY29. The company plans to resume dividends from FY28, underpinned by a resilient balance sheet and disciplined capital management.

Avecho Biotechnology is on the cusp of completing patient dosing in its pivotal Phase III CBD insomnia trial, backed by a recent $2.5 million capital raise and patent allowances in the US and Europe.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Little Green Pharma welcomes a landmark US Executive Order directing cannabis rescheduling, a move poised to reshape the global medicinal cannabis landscape.

Regis Healthcare announces the resignation of CEO Dr Linda Mellors after six years, with a transition period underway as the board searches for her successor.

Aumake Limited has obtained a Hong Kong pharmaceutical wholesale licence, enabling it to launch up to five online over-the-counter medicine stores targeting Chinese consumers. This strategic move positions the company to tap into China’s rapidly expanding OTC market.

Avecho Biotechnology has received patent allowances in the US and Europe for its proprietary CBD soft-gel formulation, reinforcing its intellectual property ahead of pivotal Phase III insomnia trial results expected in mid-2026.

Cann Group Limited has announced a dramatic 81% reduction in core debt alongside a strategic pivot to higher-margin flower products, positioning the company for its first EBITDA-positive year in FY26.

Ryman Healthcare reports a significant financial turnaround with its first positive free cash flow in over ten years, alongside upgraded sales and cost-saving targets for FY26 and completion of a major NZD 2 billion refinancing.

Little Green Pharma Ltd reported a 9.6% revenue increase to $19.2 million and slashed its net loss by 73% in the half-year ending September 2025, driven by strong growth in European medicinal cannabis markets.

Regis Healthcare reported robust FY25 financial results and outlined ambitious expansion plans targeting 10,000 beds by FY28, while urging urgent government reforms to address the sector’s undersupply of quality aged care.

Patriot Resources reports significant copper-zinc-lead assay results from its Phase 1 trenching at Kitumba, Zambia, expanding the mineralised footprint fivefold and setting the stage for further exploration.